Advertisement

On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)

      Although cholesteryl ester transfer protein (CETP) plays an important role in human lipoprotein metabolism, its relation to coronary artery disease remains controversial. The present study evaluated the relation between on-statin CETP mass and recurrent coronary events. The plasma CETP mass, measured after 4 months of statin therapy, was quantified in 3,218 patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) study. Of the 3,218 patients, 150 experienced the combined end point of recurrent myocardial infarction or death from coronary causes during a mean follow-up of 1.8 years. An increasing on-statin CETP mass was inversely related to the risk of coronary events in both unadjusted (hazard ratio [HR] per SD increase 0.77, 95% confidence interval 0.65 to 0.92, p = 0.005) and fully adjusted (HR per SD increase 0.81, 95% confidence interval 0.67 to 0.98, p = 0.027) analyses that included traditional cardiovascular risk factors. A similar trend was observed across increasing CETP mass quartiles (p trend = 0.07). A significant interaction between the CETP mass and on-treatment low-density lipoprotein (LDL) cholesterol was noted (p interaction = 0.007). A CETP mass greater than the median was associated with a decreased risk in patients with LDL cholesterol less than the median of 80 mg/dl (HR 0.52, 95% confidence interval 0.31 to 0.89, p = 0.02), but not in patients with LDL cholesterol greater than the median. In conclusion, an increasing on-statin CETP mass was inversely related to the coronary outcomes in this large clinical trial-based cohort, particularly among those with low LDL cholesterol levels. This finding is consistent with CETP facilitating reverse cholesterol transport in the setting of robust LDL clearance and might have important implications for efforts to optimally target patients with pharmacologic CETP inhibition.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tall A.
        Plasma cholesteryl ester transfer protein.
        J Lipid Res. 1993; 34: 1255-1274
        • Brousseau M.E.
        • Schaefer E.J.
        • Wolfe M.L.
        • Bloedon L.T.
        • Digenio A.G.
        • Clark R.W.
        • Mancuso J.P.
        • Rader D.J.
        Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol.
        N Engl J Med. 2004; 350: 1505-1515
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • Grundy S.M.
        • Kastelein J.J.
        • Komajda M.
        • Lopez-Sendon J.
        • Mosca L.
        • Tardif J.C.
        • Waters D.D.
        • Shear C.L.
        • Revkin J.H.
        • Buhr K.A.
        • Fisher M.R.
        • Tall A.R.
        • Brewer B.
        • ILLUMINATE Investigators
        Effects of torcetrapib in patients at high risk for coronary events.
        N Engl J Med. 2007; 357: 2109-2122
        • Nissen S.E.
        • Tardif J.C.
        • Nicholls S.J.
        • Revkin J.H.
        • Shear C.L.
        • Duggan W.T.
        • Ruzyllo W.
        • Bachinsky W.B.
        • Lasala G.P.
        • Tuzcu E.M.
        • ILLUSTRATE Investigators
        Effect of torcetrapib on the progression of coronary atherosclerosis.
        N Engl J Med. 2007; 356: 1304-1316
        • Kastelein J.J.
        • van Leuven S.I.
        • Burgess L.
        • Evans G.W.
        • Kuivenhoven J.A.
        • Barter P.J.
        • Revkin J.H.
        • Grobbee D.E.
        • Riley W.A.
        • Shear C.L.
        • Duggan W.T.
        • Bots M.L.
        • RADIANCE 1 Investigators
        Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
        N Engl J Med. 2007; 356: 1620-1630
        • Tall A.
        • Yvan-Charvet L.
        • Wang N.
        The failure of torcetrapib: was it the molecule or the mechanism?.
        Arterioscler Thromb Vasc Biol. 2007; 27: 257-260
        • Vasan R.S.
        • Pencina M.J.
        • Robins S.J.
        • Zachariah J.P.
        • Kaur G.
        • D'Agostino R.B.
        • Ordovas J.M.
        Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.
        Circulation. 2009; 120: 2414-2420
        • Ritsch A.
        • Scharnagl H.
        • Eller P.
        • Tancevski I.
        • Duwensee K.
        • Demetz E.
        • Sandhofer A.
        • Boehm B.O.
        • Winkelmann B.R.
        • Patsch J.R.
        • März W.
        Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.
        Circulation. 2010; 121: 366-374
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        • Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • Rifai N.
        • Rose L.M.
        • McCabe C.H.
        • Pfeffer M.A.
        • Braunwald E.
        • Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI22) Investigators
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Ahnadi C.
        • Berthezène F.
        • Ponsin G.
        Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.
        Atherosclerosis. 1993; 99: 219-228
        • Inazu A.
        • Koizumi J.
        • Kajinami K.
        • Kiyohar T.
        • Chichibu K.
        • Mabuchi H.
        Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and Probucol in patients with primary hypercholesterolemia and xanthoma.
        Atherosclerosis. 1999; 145: 405-413
        • van Venrooij F.V.
        • Stolk R.P.
        • Banga J.D.
        • Sijmonsma T.P.
        • van Tol A.
        • Erkelens D.W.
        • Dallinga-Thie G.M.
        • DALI Study Group
        Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
        Diabetes Care. 2003; 26: 1216-1223
        • Boekholdt S.M.
        • Kuivenhoven J.A.
        • Wareham N.J.
        • Peters R.J.
        • Jukema J.W.
        • Luben R.
        • Bingham S.A.
        • Day N.E.
        • Kastelein J.J.
        • Khaw K.T.
        Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
        Circulation. 2004; 110: 1418-1423
        • Marschang P.
        • Sandhofer A.
        • Ritsch A.
        • Fier I.
        • Kvas E.
        • Patsch J.R.
        Plasma cholesteryl transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
        J Intern Med. 2006; 260: 151-159
        • Klerkx A.H.
        • de Grooth G.J.
        • Zwinderman A.H.
        • Jukema J.W.
        • Kuivenhoven J.A.
        • Kastelein J.J.
        Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
        Eur J Clin Invest. 2004; 34: 21-28
        • Tatò F.
        • Vega G.L.
        • Tall A.R.
        • Grundy S.M.
        Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia.
        Arterioscler Thromb Vasc Biol. 1995; 15: 112-120
        • Harangi M.
        • Mirdamadi H.Z.
        • Seres I.
        • Sztanek F.
        • Molnár M.
        • Kassai A.
        • Derdák Z.
        • Illyés L.
        • Paragh G.
        Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
        Transl Res. 2009; 153: 190-198
        • Borggreve S.E.
        • Hillege H.L.
        • Dallinga-Thie G.M.
        • de Jong P.E.
        • Wolffenbuttel B.H.
        • Grobbee D.E.
        • van Tol A.
        • Dullaart R.P.
        • PREVEND Study Group
        High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides.
        Eur Heart J. 2007; 28: 1012-1018
        • Zeller M.
        • Masson D.
        • Farnier M.
        • Lorgis L.
        • Deckert V.
        • Pais de Barros J.P.
        • Desrumaux C.
        • Sicard P.
        • Grober J.
        • Blache D.
        • Gambert P.
        • Rochette L.
        • Cottin Y.
        • Lagrost L.
        High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction.
        J Am Coll Cardiol. 2007; 50: 1948-1955
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • Brewer Jr, H.B.
        • Clark L.T.
        • Hunninghake D.B.
        • Pasternak R.C.
        • Smith Jr, S.C.
        • Stone N.J.
        • National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Regieli J.J.
        • Jukema J.W.
        • Grobbee D.E.
        • Kastelein J.J.
        • Kuivenhoven J.A.
        • Zwinderman A.H.
        • van der Graaf Y.
        • Bots M.L.
        • Doevendans P.A.
        CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
        Eur Heart J. 2008; 29: 2792-2799
        • Thompson A.
        • Di Angelantonio E.
        • Sarwar N.
        • Erqou S.
        • Saleheen D.
        • Dullaart R.P.
        • Keavney B.
        • Ye Z.
        • Danesh J.
        Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.
        JAMA. 2008; 299: 2777-2788
        • Schwartz C.
        • VandenBroek J.
        • Cooper P.
        Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans.
        J Lipid Res. 2004; 45: 1594-1607
        • Tanigawa H.
        • Billheimer J.T.
        • Tohyama J.
        • Zhang Y.
        • Rothblat G.
        • Rader D.J.
        Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport.
        Circulation. 2007; 116: 1267-1273
        • Endo A.
        The discovery and development of HMG-CoA Reductase Inhibitors.
        J Lipid Res. 1992; 33: 1569-1582
        • McPherson R.
        • Mann C.J.
        • Tall A.R.
        • Hogue M.
        • Martin L.
        • Milne R.W.
        • Marcel Y.L.
        Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia.
        Arterioscler Thromb. 1991; 11: 797-804